Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942160 · ClinicalTrials.gov registry record · Phase 2
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 259
- Enrollment target
NCT02942160: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT02942160 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 259 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02942160, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 259 participants
- Enrollment target
Study Summary
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
Interventions
- BIOLOGICAL Collagenase Clostridium Histolyticum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2018-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02942160
The ClinicalTrials.gov registry entry for NCT02942160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Collagenase Clostridium Histolyticum is the first listed.
NCT02942160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02942160 about?
NCT02942160 is a clinical study titled "EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)". A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
What is the current status of trial NCT02942160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2016-10-05. Estimated completion is 2018-06-14.
What interventions are being tested in trial NCT02942160?
The interventions under investigation include: Collagenase Clostridium Histolyticum (BIOLOGICAL).
Who is sponsoring clinical trial NCT02942160?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.